Black Titan (NASDAQ:BTTC) Releases Earnings Results

Black Titan (NASDAQ:BTTC) issued its earnings results on Friday. The company reported ($0.22) EPS for the quarter, FiscalAI reports.

Black Titan Price Performance

Shares of BTTC stock opened at $0.90 on Friday. The stock’s fifty day moving average is $1.22. Black Titan has a 12-month low of $0.86 and a 12-month high of $39.00. The company has a market capitalization of $9.67 million, a P/E ratio of -0.30 and a beta of 1.20.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in BTTC. Armistice Capital LLC acquired a new position in Black Titan during the fourth quarter worth $840,000. Marex Group plc acquired a new position in Black Titan during the fourth quarter worth $84,000. HRT Financial LP acquired a new position in Black Titan during the fourth quarter worth $28,000. Finally, Renaissance Technologies LLC acquired a new position in Black Titan during the fourth quarter worth $26,000.

Black Titan Company Profile

Titan Pharmaceuticals, Inc is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.